Literature DB >> 26598527

Bimatoprost (0.03%)-induced accommodative spasm and pseudomyopia.

Debananda Padhy1, Aparna Rao2.   

Abstract

Bimatoprost is a prostaglandin analogue used topically in the treatment of glaucoma. Commonly known side effects include eyelash growth, iris pigmentation and conjunctival hyperemia. While pseudomyopia is reported to be caused by parasympathomimetics, such an effect precipitated by bimatoprost has not yet been reported. We report a case demonstrating pseudomyopia and accommodative spasm caused after starting bimatoprost 0.03% in a young patient with glaucoma. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26598527      PMCID: PMC4680562          DOI: 10.1136/bcr-2015-211820

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture.

Authors:  J W Stjernschantz
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-05       Impact factor: 4.799

2.  Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.

Authors:  Enyr S Arcieri; Alessandro Santana; Fabiano N Rocha; Gustavo L Guapo; Vital P Costa
Journal:  Arch Ophthalmol       Date:  2005-02

3.  Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia.

Authors:  K Miyake; I Ota; N Ibaraki; J Akura; S Ichihashi; Y Shibuya; K Maekubo; S Miyake
Journal:  Arch Ophthalmol       Date:  2001-03

4.  Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost.

Authors:  M C Lima; A Paranhos; S Salim; R Honkanen; L Devgan; M Wand; A R Gaudio; M B Shields
Journal:  J Glaucoma       Date:  2000-08       Impact factor: 2.503

5.  Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients.

Authors:  R E Warwar; J D Bullock; D Ballal
Journal:  Ophthalmology       Date:  1998-02       Impact factor: 12.079

6.  In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.

Authors:  Jean-Marc Guenoun; Christophe Baudouin; Patrice Rat; Aude Pauly; Jean-Michel Warnet; Françoise Brignole-Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-07       Impact factor: 4.799

7.  Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.

Authors:  William C Stewart; Allan E Kolker; Jeanette A Stewart; Jessica Leech; Angi L Jackson
Journal:  Am J Ophthalmol       Date:  2003-03       Impact factor: 5.258

8.  Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study.

Authors:  M Cellini; R Caramazza; D Bonsanto; B Bernabini; E C Campos
Journal:  Ophthalmologica       Date:  2004 Sep-Oct       Impact factor: 3.250

9.  Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes.

Authors:  R S Ayyala; D A Cruz; C E Margo; L E Harman; S E Pautler; D M Misch; J A Mines; D W Richards
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

10.  Uveal effusion induced by topical travoprost in a patient with Sturge-Weber-Krabbe syndrome.

Authors:  J Gambrelle; P Denis; V Kocaba; J D Grange
Journal:  J Fr Ophtalmol       Date:  2008-11       Impact factor: 0.818

View more
  2 in total

1.  Pseudomyopia with paradoxical accommodation: a case report.

Authors:  In Ki Park; Young Kee Park; Jae-Ho Shin; Yeoun Sook Chun
Journal:  BMC Ophthalmol       Date:  2021-03-31       Impact factor: 2.209

Review 2.  Pseudomyopia: A Review.

Authors:  María García-Montero; Gema Felipe-Márquez; Pedro Arriola-Villalobos; Nuria Garzón
Journal:  Vision (Basel)       Date:  2022-03-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.